GlassScriptPhysician profile
Feifan Tang
NPI 1568150035
$5,291.26
in general payments reported to CMS, 2019-2025
31 companies · $3,039 in 2025
The $3,039 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $27.82 · 2024: $2,224 · 2025: $3,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,291.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $686.92 | 2024-2025 | Airsupra, Breztri, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $538.12 | 2024-2025 | |
| Ardelyx, INC. | $480.32 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $473.98 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $356.47 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $346.01 | 2024-2025 | Voquezna |
| Amgen INC. | $306.60 | 2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $230.93 | 2024-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.66 | 2024-2025 | Jardiance |
| Axsome Therapeutics, INC. | $186.41 | 2025 | Symbravo, Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.08 | 2025 | Xifaxan |
| Pfizer INC. | $141.74 | 2023-2025 | |
| Genzyme Corporation | $135.35 | 2025 | |
| Merck Sharp & Dohme LLC | $122.69 | 2024-2025 | Verquvo |
| Madrigal Pharmaceuticals | $121.34 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $114.53 | 2024-2025 | Tymlos |
| Abbvie INC. | $95.00 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $93.22 | 2024 | |
| Sun Pharmaceutical Industries INC. | $90.67 | 2024-2025 | |
| Corcept Therapeutics | $56.60 | 2024-2025 | Korlym |
| Oyster Point Pharma, INC. | $52.18 | 2024-2025 | Tyrvaya |
| Kowa Pharmaceuticals America, INC. | $47.42 | 2025 | Zoryve |
| Alk-Abello, INC | $44.33 | 2025 | Ragwitek, Grastek, Odactra |
| Janssen Pharmaceuticals, INC | $42.85 | 2024 | Xarelto |
| Novo Nordisk INC | $41.80 | 2024-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $40.15 | 2025 | |
| Sumitomo Pharma America, INC. | $24.65 | 2025 | Gemtesa |
| Averitas Pharma INC. | $21.14 | 2025 | Qutenza |
| Exact Sciences Corporation | $21.01 | 2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $19.70 | 2025 | |
| Vivus LLC | $17.39 | 2024 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feifan Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.